Cochrane Review Says New Alzheimer’s Drugs Offer No Meaningful Benefit

A new Cochrane review finds that anti‑amyloid Alzheimer’s drugs Leqimbi and Kisunla offer no meaningful clinical benefit.

The finding matters because both medicines were approved by the U.S. Food and Drug Administration this year—Leqimbi in January 2023 and Kisunla in July 2023, and have been billed as breakthroughs that could change how the disease is treated, an expectation that has driven costly insurance coverage and patient hopes. ^[1] If the drugs do not alter disease trajectory, patients may face high out‑of‑pocket costs without clear benefit.

The review, published in June 2024, examined all available randomized trials and concluded that the drugs did not produce a statistically significant improvement in cognitive outcomes compared with placebo. ^[3] The authors said the treatments “make no meaningful difference” in slowing disease progression. ^[3]

"We have to turn down pitches because the drugs aren't delivering the expected benefits," said the director of the Columbus Memory Center. ^[2] The center, located in Ohio, has seen a slowdown in enrollment for clinical studies that rely on these therapies, reflecting growing skepticism among clinicians.

MarketWatch said the drugs were initially hailed as breakthroughs, but a new report casts doubt on their efficacy. ^[1] The reporter noted that the hype surrounding anti‑amyloid approaches may have outpaced the underlying science.

Other outlets have presented conflicting views. IFLScience said the drugs have no meaningful effects and have sparked debate among scientists. ^[4] Earlier MSN coverage, however, said the medicines could transform treatment, highlighting the ongoing controversy.

Patients, families, and insurers now must weigh the high price of these infusions against uncertain clinical gains. The FDA’s accelerated approval pathway, which allowed the drugs to enter the market on the basis of surrogate biomarkers, may come under renewed scrutiny as real‑world effectiveness data accumulate.

**What this means** The review underscores a gap between biomarker‑driven approval and tangible patient outcomes. Policymakers may consider tighter post‑market surveillance and stricter reimbursement criteria, while researchers are likely to refocus on therapeutic strategies that address disease mechanisms beyond amyloid clearance.